ponesimod
Trade name: Ponvory
Small moleculeapproved
Approved
Mar 18, 2021
Ponesimod, sold under the brand name Ponvory, is a medication for the treatment of multiple sclerosis. It is a sphingosine-1-phosphate receptor modulator. — Wikipedia
Clinical trial activity
15 trials · 3 clinical orgs · 3 marketing orgs
Phase 1
7
Phase 2
8
Phase 3
3
Phase 4
0
Earliest trial started Oct 1, 2008 (NCT00852670)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 3 Sponsor(trial)
2020s
- Mar 18, 2021
Johnson and Johnson — Earliest FDA Approval
- Mar 18, 2021
Janssen Pharmaceutica NV — Marketing Organization
- Mar 18, 2021
Johnson and Johnson — NDA Secondary Org
- Mar 18, 2021
Johnson and Johnson — NDA Organization
- Mar 18, 2021
Vanda Pharmaceuticals — Marketing Organization
Indications
Approved for
Mechanism of action
S1PR1 agonist
Approval history
- approvedMar 18, 2021
Chemistry & pharmacology
Loading structure…
SMILES
CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C- Mol. weight
- 460.98 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaPonesimod ↗
- ChEMBLCHEMBL1096146 ↗
Also known as
- 5-(3-chloro-4-(2,3-dihydroxy-propoxy)benzylidene)-2-propylimino-3-o-tolyl-thiazolidin-4-one
- act128800
- act 128800
- act-128800
- act-128800
- act-128800
- act-128800
- act-128800
- ponesimod
- ponesimod
- ponesimod
- ponesimod
- ponesimod
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05552196 | Phase 1 | Oct 18, 2022 | Janssen Pharmaceutica NV |
| NCT03882255 | Phase 1 | Mar 20, 2019 | Janssen Pharmaceutica NV |
| NCT03232073 | Phase 3 | Jul 17, 2017 | Actelion |
| NCT02907177 | Phase 3 | Mar 30, 2017 | Actelion |
| NCT02461134 | Phase 2 | Feb 1, 2016 | Actelion |
| NCT02425644 | Phase 3 | Apr 1, 2015 | Actelion |
| NCT02068235 | Phase 1 | Aug 1, 2014 | Actelion |
| NCT02136888 | Phase 1 | Aug 1, 2011 | Actelion |
| NCT01208090 | Phase 2 | Oct 1, 2010 | Actelion |
| NCT01093326 | Phase 2 | May 1, 2010 | Actelion |
| NCT02029482 | Phase 1 | Apr 1, 2010 | Actelion, IQVIA |
| NCT01006265 | Phase 2 | Oct 1, 2009 | Actelion |
| NCT02126956 | Phase 1 | Mar 1, 2009 | Actelion |
| NCT02223832 | Phase 1 | Feb 1, 2009 | Actelion |
| NCT00852670 | Phase 2 | Oct 1, 2008 | Actelion |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Actelion | For profit | 13 | 13 | 3 | 2008 |
| Janssen Pharmaceutica NV | For profit | 2 | 2 | 1 | 2019 |
| IQVIA | For profit | 1 | 0 | 1 | 2010 |
3 organizations
Page 1 / 1
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | MKTG | Mar 18, 2021 |
| Johnson and Johnson | For profit | NDA2 | Mar 18, 2021 |
| Johnson and Johnson | For profit | NDA | Mar 18, 2021 |
| Vanda Pharmaceuticals | For profit | MKTG | Mar 18, 2021 |